



## Vaxart, Inc. to Participate in September Virtual Investor Conferences

September 3, 2020

- H.C. Wainwright: 22<sup>nd</sup> Annual Global Investment Conference - September 14<sup>th</sup> – 16<sup>th</sup>
- Sachs Associates: 20<sup>th</sup> Annual Biotech in Europe Forum - September 21<sup>st</sup> – 24<sup>th</sup>
- SVB Leerink: CybeRx Series: Vaccine Forum - September 23<sup>rd</sup> & – 24<sup>th</sup>

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced senior management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

### *H.C. Wainwright: 22<sup>nd</sup> Annual Global Investment Conference*

Title: **Vaxart, Inc. (VXRT) Company Presentation / Fireside Chat**  
Date: Monday, September 14<sup>th</sup> 2020  
Time: 10:30 am Eastern Time  
Presenter: Andrei Floroiu, *President & CEO*

### *Sachs Associates: 20<sup>th</sup> Annual Biotech in Europe Forum*

Title (1): **Pandemic Response Day: Vaccine Panel**  
Date: Monday, September 21<sup>st</sup> 2020  
Time: 13:05 -14:00 Central European Time  
Panelists: Andrei Floroiu, *President & CEO Vaxart, Inc.*  
Andrew Allen, *Co-Founder, President & CEO, Gritstone Oncology*  
Frederic Ors, *CEO, IMV, Inc.*  
Johan Van Hoof, *Global Therapeutic Area Head, IDV Vaccines, Johnson & Johnson*

Title (2): **Spotlight Showcase Vaxart, Inc. (VXRT) Company Presentation**  
Date: Monday, September 21<sup>st</sup> 2020  
Time: 14:05 -14:25 Central European Time  
Presenter: Andrei Floroiu, *President & CEO Vaxart, Inc.*

### *SVB LEERINK: CybeRx Series – Vaccine Forum*

Title: **Vaxart, Inc. (VXRT) - Fireside Chat**  
Date: Wednesday, September 23<sup>rd</sup> 2020  
Time: 2:00 am Eastern Time  
Presenters: Andrei Floroiu, *President & CEO*  
Sean Tucker, Ph.D., *Founder & Chief Scientific Officer*

### **Webcast Links**

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Company's website.

### **About Vaxart**

Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet vaccine is easier to distribute, store and administer than injectable vaccines and may provide significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart's development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit [www.vaxart.com](http://www.vaxart.com).

### **Contacts**

Investors:  
Joyce Allaire  
LifeSci Advisors  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)  
617.435.6602

Media:  
Gloria Gasaatura  
LifeSci Communications  
[GGasaatura@lifescicomms.com](mailto:GGasaatura@lifescicomms.com)  
646.970.4688



Source: Vaxart, Inc.